To evaluate the safety , tolerability and bioactivity of ascending doses of MP0112 , a designed ankyrin repeat protein ( DARPin ) that binds with high affinity to vascular endothelial growth factor-A ( VEGF-A ) , in treatment-naive patients with exudative age-related macular degeneration ( AMD ) .